questionsmedicales.fr
Enzymes et coenzymes
Enzymes
Transferases
Phosphotransferases
Phosphotransferases (Phosphate Group Acceptor)
Phosphotransferases (Phosphate Group Acceptor) : Questions médicales fréquentes
Termes MeSH sélectionnés :
Cognitive Behavioral Therapy
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Phosphotransferases (Phosphate Group Acceptor) : Questions médicales les plus fréquentes",
"headline": "Phosphotransferases (Phosphate Group Acceptor) : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Phosphotransferases (Phosphate Group Acceptor) : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-31",
"dateModified": "2025-04-27",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Phosphotransferases (Phosphate Group Acceptor)"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Phosphotransferases",
"url": "https://questionsmedicales.fr/mesh/D010770",
"about": {
"@type": "MedicalCondition",
"name": "Phosphotransferases",
"code": {
"@type": "MedicalCode",
"code": "D010770",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Adenylate kinase",
"alternateName": "Adenylate Kinase",
"url": "https://questionsmedicales.fr/mesh/D000263",
"about": {
"@type": "MedicalCondition",
"name": "Adenylate kinase",
"code": {
"@type": "MedicalCode",
"code": "D000263",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.650.025"
}
}
},
{
"@type": "MedicalWebPage",
"name": "ATP synthetase complexes",
"alternateName": "ATP Synthetase Complexes",
"url": "https://questionsmedicales.fr/mesh/D025181",
"about": {
"@type": "MedicalCondition",
"name": "ATP synthetase complexes",
"code": {
"@type": "MedicalCode",
"code": "D025181",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.650.150"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Guanylate kinase",
"alternateName": "Guanylate Kinases",
"url": "https://questionsmedicales.fr/mesh/D051528",
"about": {
"@type": "MedicalCondition",
"name": "Guanylate kinase",
"code": {
"@type": "MedicalCode",
"code": "D051528",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.650.450"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Nucleoside diphosphate kinase",
"alternateName": "Nucleoside-Diphosphate Kinase",
"url": "https://questionsmedicales.fr/mesh/D009701",
"about": {
"@type": "MedicalCondition",
"name": "Nucleoside diphosphate kinase",
"code": {
"@type": "MedicalCode",
"code": "D009701",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.650.550"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "NM23 Nucleoside Diphosphate kinases",
"alternateName": "NM23 Nucleoside Diphosphate Kinases",
"url": "https://questionsmedicales.fr/mesh/D054778",
"about": {
"@type": "MedicalCondition",
"name": "NM23 Nucleoside Diphosphate kinases",
"code": {
"@type": "MedicalCode",
"code": "D054778",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.650.550.200"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Nucleoside phosphate kinase",
"alternateName": "Nucleoside-Phosphate Kinase",
"url": "https://questionsmedicales.fr/mesh/D009703",
"about": {
"@type": "MedicalCondition",
"name": "Nucleoside phosphate kinase",
"code": {
"@type": "MedicalCode",
"code": "D009703",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.650.575"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Phosphotransferases (Phosphate Group Acceptor)",
"alternateName": "Phosphotransferases (Phosphate Group Acceptor)",
"code": {
"@type": "MedicalCode",
"code": "D017856",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Jean-Marc Jeckelmann",
"url": "https://questionsmedicales.fr/author/Jean-Marc%20Jeckelmann",
"affiliation": {
"@type": "Organization",
"name": "Institute of Biochemistry and Molecular Medicine, University of Bern, Bühlstrasse 28, 3012, Bern, Switzerland. jean-marc.jeckelmann@ibmm.unibe.ch."
}
},
{
"@type": "Person",
"name": "Zengqi Xie",
"url": "https://questionsmedicales.fr/author/Zengqi%20Xie",
"affiliation": {
"@type": "Organization",
"name": "Institute of Polymer Optoelectronic Materials and Devices, South China University of Technology, Guangzhou 510640, China."
}
},
{
"@type": "Person",
"name": "Bernhard Erni",
"url": "https://questionsmedicales.fr/author/Bernhard%20Erni",
"affiliation": {
"@type": "Organization",
"name": "Institute of Biochemistry and Molecular Medicine, University of Bern, Bühlstrasse 28, 3012, Bern, Switzerland."
}
},
{
"@type": "Person",
"name": "Yulin Zhu",
"url": "https://questionsmedicales.fr/author/Yulin%20Zhu",
"affiliation": {
"@type": "Organization",
"name": "Shenzhen Grubbs Institute and Department of Chemistry, Southern University of Science and Technology, Shenzhen 518055, China."
}
},
{
"@type": "Person",
"name": "Feng He",
"url": "https://questionsmedicales.fr/author/Feng%20He",
"affiliation": {
"@type": "Organization",
"name": "Shenzhen Grubbs Institute and Department of Chemistry, Southern University of Science and Technology, Shenzhen 518055, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Acceptability of Cognitive Behavioral Therapy for Tinnitus: A Study With Veterans and Nonveterans.",
"datePublished": "2023-08-11",
"url": "https://questionsmedicales.fr/article/37566882",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1044/2023_AJA-23-00020"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cognitive behavioral therapies for individuals with cerebral palsy: A scoping review.",
"datePublished": "2023-02-01",
"url": "https://questionsmedicales.fr/article/36725690",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/dmcn.15507"
}
},
{
"@type": "ScholarlyArticle",
"name": "Using values in cognitive and behavioral therapy: A bridge back to philosophy.",
"datePublished": "2023-05-24",
"url": "https://questionsmedicales.fr/article/37226577",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/jep.13872"
}
},
{
"@type": "ScholarlyArticle",
"name": "Culturally Responsive Cognitive Behavioral Therapy for Ethnically Diverse Populations.",
"datePublished": "2023-02-28",
"url": "https://questionsmedicales.fr/article/36854287",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1146/annurev-clinpsy-080921-072750"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Intensive cognitive behavioral group therapy for the treatment of panic disorder].",
"datePublished": "2023-10-22",
"url": "https://questionsmedicales.fr/article/37865926",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1556/650.2023.32892"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Transferases",
"item": "https://questionsmedicales.fr/mesh/D014166"
},
{
"@type": "ListItem",
"position": 5,
"name": "Phosphotransferases",
"item": "https://questionsmedicales.fr/mesh/D010770"
},
{
"@type": "ListItem",
"position": 6,
"name": "Phosphotransferases (Phosphate Group Acceptor)",
"item": "https://questionsmedicales.fr/mesh/D017856"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Phosphotransferases (Phosphate Group Acceptor) - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-05",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Comment diagnostiquer une déficience en phosphotransférases ?\nQuels tests sont utilisés pour évaluer l'activité des phosphotransférases ?\nQuels symptômes peuvent indiquer un problème avec ces enzymes ?\nLes tests génétiques sont-ils utiles pour le diagnostic ?\nPeut-on diagnostiquer par imagerie des troubles liés aux phosphotransférases ?",
"url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Cognitive+Behavioral+Therapy&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Quels sont les symptômes d'une déficience en phosphotransférases ?\nLes troubles neurologiques sont-ils liés aux phosphotransférases ?\nComment les symptômes varient-ils selon le type d'enzyme ?\nLes symptômes apparaissent-ils à la naissance ?\nY a-t-il des symptômes spécifiques aux enfants ?",
"url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Cognitive+Behavioral+Therapy&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Peut-on prévenir les déficiences en phosphotransférases ?\nLes tests de dépistage néonatal sont-ils utiles ?\nY a-t-il des recommandations diététiques préventives ?\nLes conseils génétiques sont-ils importants ?\nLes vaccinations peuvent-elles aider à prévenir des complications ?",
"url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Cognitive+Behavioral+Therapy&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Quels traitements sont disponibles pour les déficiences en phosphotransférases ?\nLa thérapie génique est-elle une option ?\nLes médicaments peuvent-ils aider à traiter ces déficiences ?\nY a-t-il des traitements expérimentaux en cours ?\nComment la gestion diététique aide-t-elle ?",
"url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Cognitive+Behavioral+Therapy&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Quelles complications peuvent survenir avec ces déficiences ?\nLes troubles cardiaques sont-ils une complication possible ?\nComment les complications affectent-elles la qualité de vie ?\nLes complications sont-elles réversibles ?\nY a-t-il un risque accru de maladies métaboliques ?",
"url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Cognitive+Behavioral+Therapy&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Quels sont les facteurs de risque pour ces déficiences ?\nLes facteurs environnementaux jouent-ils un rôle ?\nLes maladies auto-immunes sont-elles un facteur de risque ?\nL'alimentation peut-elle influencer le risque ?\nLes infections peuvent-elles aggraver la condition ?",
"url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Cognitive+Behavioral+Therapy&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en phosphotransférases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques et des analyses biochimiques sont utilisés pour évaluer l'activité des phosphotransférases."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité des phosphotransférases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de dosage enzymatique et les analyses de métabolites sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec ces enzymes ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes métaboliques, comme la fatigue ou des troubles énergétiques, peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils utiles pour le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier des mutations affectant les phosphotransférases."
}
},
{
"@type": "Question",
"name": "Peut-on diagnostiquer par imagerie des troubles liés aux phosphotransférases ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie n'est pas spécifique, mais peut aider à évaluer des complications métaboliques."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une déficience en phosphotransférases ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, faiblesse musculaire, troubles de la croissance et anomalies métaboliques."
}
},
{
"@type": "Question",
"name": "Les troubles neurologiques sont-ils liés aux phosphotransférases ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles neurologiques peuvent survenir en raison d'un métabolisme énergétique altéré."
}
},
{
"@type": "Question",
"name": "Comment les symptômes varient-ils selon le type d'enzyme ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes dépendent de l'enzyme spécifique affectée et de son rôle métabolique."
}
},
{
"@type": "Question",
"name": "Les symptômes apparaissent-ils à la naissance ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains symptômes peuvent apparaître à la naissance, tandis que d'autres se développent plus tard."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques aux enfants ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les enfants peuvent présenter des retards de développement et des troubles de la croissance."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les déficiences en phosphotransférases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un diagnostic précoce peut aider à gérer les symptômes."
}
},
{
"@type": "Question",
"name": "Les tests de dépistage néonatal sont-ils utiles ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests de dépistage néonatal peuvent identifier certaines déficiences précocement."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations diététiques préventives ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recommandations diététiques peuvent être établies pour les familles à risque."
}
},
{
"@type": "Question",
"name": "Les conseils génétiques sont-ils importants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les conseils génétiques peuvent aider les familles à comprendre les risques de transmission."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles aider à prévenir des complications ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccinations ne préviennent pas directement les déficiences, mais protègent contre les infections."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les déficiences en phosphotransférases ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement peut inclure des suppléments nutritionnels et une gestion diététique."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est en recherche, mais pas encore largement disponible pour ces déficiences."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider à traiter ces déficiences ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments peuvent aider à gérer les symptômes, mais ne corrigent pas la déficience."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux en cours ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des études cliniques explorent de nouvelles approches thérapeutiques pour ces conditions."
}
},
{
"@type": "Question",
"name": "Comment la gestion diététique aide-t-elle ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une gestion diététique peut aider à compenser les déficiences métaboliques et à améliorer la santé."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec ces déficiences ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications métaboliques, neurologiques et de croissance peuvent se développer."
}
},
{
"@type": "Question",
"name": "Les troubles cardiaques sont-ils une complication possible ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles cardiaques peuvent survenir en raison d'un métabolisme énergétique altéré."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent réduire la qualité de vie en limitant les activités quotidiennes."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de maladies métaboliques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes avec des déficiences en phosphotransférases peuvent avoir un risque accru de maladies métaboliques."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour ces déficiences ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux et certaines mutations génétiques sont des facteurs de risque connus."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux jouent-ils un rôle ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains facteurs environnementaux peuvent influencer l'expression des déficiences enzymatiques."
}
},
{
"@type": "Question",
"name": "Les maladies auto-immunes sont-elles un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines maladies auto-immunes peuvent affecter le métabolisme et augmenter le risque."
}
},
{
"@type": "Question",
"name": "L'alimentation peut-elle influencer le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation déséquilibrée peut exacerber les symptômes chez les personnes à risque."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles aggraver la condition ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections peuvent déclencher ou aggraver les symptômes liés aux déficiences enzymatiques."
}
}
]
}
]
}
Cognitive behavioral therapy (CBT) is a gold standard yet underutilized treatment for tinnitus, and tinnitus is especially highly prevalent among veterans. The aims of this study were twofold: to dete...
This cross-sectional study was conducted online with a sample of 277 adults in the United States who self-reported at least some level of bothersome tinnitus in the past week. The sample for this stud...
Among 277 participants, 147 (53.07%) reporting gender were women, 216 (77.98%) reporting race/ethnicity were White, and 129 (46.57%) were veterans of any branch of the U.S. Armed Forces. Veteran ratin...
Despite strong research support, CBT was rated as less acceptable than a different, less widely empirically supported treatment. Veterans' ratings of acceptability were lower than those of nonveterans...
To synthesize the evidence about the main intervention characteristics of cognitive behavioral therapies (CBTs) for individuals with cerebral palsy and identify barriers and facilitators to their succ...
A scoping review methodology informed a literature search for papers published between 1991 and 2021. Articles were screened, reviewed, and categorized using the DistillerSR systematic review software...
Out of 1265 publications identified, 14 met the inclusion criteria. Elements associated with the specific study participant characteristics (46% female; aged 6-65 years), type of CBT techniques used (...
This study highlights the high flexibility within CBT interventions, enabling their adaptation for individuals with cerebral palsy. However, relatively little, and only low-certainty evidence was iden...
Ancient therapeutic practices have influenced the development of cognitive behavioral therapy (CBT) theories such as Albert Ellis's rational emotive behavior therapy and Aaron Beck's cognitive therapy...
Cognitive behavioral therapy (CBT) is often referred to as the "gold standard" treatment for mental health problems, given the large body of evidence supporting its efficacy. However, there are persis...
Panic disorder is one of the most commonly occurring emotional disorder, showing increased prevalence rates since the COVID-19 pandemic. The ever-growing number of patients in need of treatment is a h...
Based on Salkovskis and Clark (1986), we developed a 5 session, intensive cognitive behavioral group therapy protocol for panic patients....
Effectiveness of the short group therapy was assessed with questionnaires (Spielberger's State-Trait Anxiety Inventory, Beck Depression Inventory) and an additional subjective scale. Paired sample t-t...
Our results suggest that the intensity of anxiety and depressive symptoms (t(36) = 5.497, p<0.0001; Z = -4.871, p<0.0001) as well as the frequency of panic attacks (Z= -5.190, p<0.0001) decreased sign...
Our clinical study provides further evidence by the effectiveness of low-intensity psychological interventions, offering an evidence-based protocol for professionals working in primary as well as ment...
We tested the predictions from Beck's cognitive theory that change in cognitive distortions precedes and predicts change in affective symptoms of depression, and his secondary prediction that change i...
There is substantial evidence that cognitive behavioral therapy (CBT) and mindfulness-based cognitive therapy (MBCT) improve symptoms and functioning in adults with mood and psychotic disorders. There...
We conducted a randomized controlled trial comparing remotely administered group CBT to group MBCT for adolescents (ages 13-17) with a mood disorder or attenuated psychosis symptoms. Adolescents atten...
Sixty-six youth (...
The beneficial effect of both treatments in a group telehealth format is encouraging. Due to our limited sample, future research should investigate whether adolescents' history of adversity and treatm...
Identifying active ingredients of psychological interventions is a major goal of psychotherapy researchers that is often justified by the promise that it will lead to improved patient outcomes. Much o...
Endometriosis is an inflammatory disease that affects women of reproductive age, causing pain and the possibility of infertility. Endometriosis was associated to low life quality and research shows th...
The aim of the present systematic review was to explore the field of psychology in endometriosis, identifying studies that used the cognitive behavioral therapy technique as a treatment for endometrio...
The keywords used were...
Of the 129 articles found, only 5 were selected, and it was possible to identify that the psychological intervention whose approach brought cognitive-behavioral therapy techniques promoted a decrease ...
Cognitive-behavioral therapy can be very promising to take care of the emotional side of those who have endometriosis However, the present systematic review highlights the need to develop more structu...
The effects of dialectical behavior therapy on generalized anxiety disorder have not been examined to date, whereas cognitive behavioral therapy is a well-known psychotherapy for generalized anxiety d...
This study investigated the effects of cognitive behavioral therapy versus dialectical behavior therapy on executive function and reduction of symptoms in generalized anxiety disorder....
In the present study, 72 generalized anxiety disorder patients were randomly assigned to one of two groups: dialectical behavior therapy or cognitive behavioral therapy. Evaluations were performed at ...
Although depression and anxiety symptoms were significantly reduced by cognitive behavioral therapy, dialectical behavior therapy was more effective for improving executive function....